In summary (Table 4), the prediction suggests that EPHA2 is upregulated in NSCLC through the repression of TP63 and suppression of CCND1; in SCLC, the suppression of EGFR does not affect EPHA2; therefore, we should expect higher level of EPHA2 in NSCLC samples. The gene discussed is EPHA2; the disease is small cell lung carcinoma.